Introduction: Twelve modifiable risk factors (RFs) account for 40% of dementia cases worldwide. However, limited data exist on such factors in middle- and low-income countries. We aimed to estimate the population-attributable ...
Background: In recent years, there has been an increase in the number of case reports of families with autosomal dominant Alzheimer's disease (ADAD) in Latin America (LA). Nevertheless, little is known about the clinical ...
Wagemann, Olivia; Liu, Haiyan; Wang, Guoqiao; Shi, Xinyu; Bittner, Tobias; Scelsi, Marzia A.; Farlow, Martin R.; Clifford, David B.; Supnet Bell, Charlene; Santacruz, Anna M.; Aschenbrenner, Andrew J.; Hassenstab, Jason J.; Benzinger, Tammie L.S.; Gordon, Brian A.; Coalier, Kelley A.; Cruchaga, Carlos; Ibanez, Laura; Perrin, Richard J.; Xiong, Chengjie; Li, Yan; Morris, John C.; Lah, James J.; Berman, Sarah B.; Roberson, Erik D.; van Dyck, Christopher H.; Galasko, Douglas; Gauthier, Serge; Hsiung, Ging-Yuek R.; Brooks, William S.; Pariente, Jérémie; Mummery, Catherine J.; Day, Gregory S.; Ringman, John M.; Chrem Méndez, Patricio Alexis; Dominantly Inherited Alzheimer Network–Trials Unit(American Medical Association, 2024-06-01)
Importance: Effects of antiamyloid agents, targeting either fibrillar or soluble monomeric amyloid peptides, on downstream biomarkers in cerebrospinal fluid (CSF) and plasma are largely unknown in dominantly inherited ...
Sosa, Ana Luisa; Brucki, Sonia M.; Crivelli, Lucía; Lopera, Francisco Javier; Acosta, Daisy M.; Acosta Uribe, Juliana; Aguilar, Diego; Aguilar Navarro, Sara G.; Allegri, Ricardo Francisco; Bertolucci, Paulo H.; Calandri, Ismael Luis; Carrillo, María C.; Chrem Méndez, Patricio Alexis; Cornejo Olivas, Mario; Custodio, Nilton; Damián, Andrés; Cruz de Souza, Leonardo; Duran Aniotz, Claudia; García, Adolfo M.; Sevlever, Gustavo Emilio(John Wiley & Sons, 2024-05-27)
Introduction: While Latin America (LatAm) is facing an increasing burden of dementia due to the rapid aging of the population, it remains underrepresented in dementia research, diagnostics, and care.
Methods: In 2023, ...
Ongoing assessment of patients with Alzheimer's disease (AD) in postapproval studies is important for mapping disease progression and evaluating real-world treatment effectiveness and safety. However, interpreting outcomes ...
Amnestic mild cognitive impairment (aMCI) is defined by memory impairment but executive function (EF) deficits could be also a common feature. This study examined the underlying neurocognitive processes associated with ...
Iaccarino, Leonardo; Llibre Guerra, Jorge J.; McDade, Eric; Edwards, Lauren; Gordon, Brian A.; Benzinger, Tammie L.S.; Hassenstab, Jason; Kramer, Joel H.; Li, Yan; Miller, Bruce L.; Miller, Zachary; Morris, John C.; Mundada, Nidhi; Perrin, Richard J.; Rosen, Howard J.; Soleimani Meigooni, David; Strom, Amelia; Tsoy, Elena; Wang, Guoqiao; Xiong, Chengjie; Allegri, Ricardo Francisco; Chrem Méndez, Patricio Alexis; Vázquez, Silvia(Oxford University Press, 2024-05-03)
Approximately 5% of Alzheimer's disease patients develop symptoms before age 65 (early-onset Alzheimer's disease), with either sporadic (sporadic early-onset Alzheimer's disease) or dominantly inherited (dominantly inherited ...
Introduction: Recent growth in the functionality and use of technology has prompted an increased interest in the potential for remote or decentralized clinical trials in dementia. There are many potential benefits associated ...
Background: In people with genetic forms of Alzheimer's disease, such as in Down syndrome and autosomal-dominant Alzheimer's disease, pathological changes specific to Alzheimer's disease (ie, accumulation of amyloid and ...
Introduction: Amyloid beta and tau pathology are the hallmarks of sporadic Alzheimer's disease (AD) and autosomal dominant AD (ADAD). However, Lewy body pathology (LBP) is found in ≈ 50% of AD and ADAD brains.
Methods: ...